[The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist's treatment: A review].
Irina BobkovaPublished in: Terapevticheskii arkhiv (2023)
The renin-angiotensin-aldosterone system (RAAS) activation plays a key role in the chronic kidney disease (CKD) progression and in the cardiovascular complications (CVC) development in patients with diabetes mellitus (DM). RAAS blockers alone are not sufficient to prevent CVC and CVC progression. RAAS upregulation in CKD associated with DM triggers the mineralocorticoid receptors (MCR) hyperactivation which results in fibrosis and inflammation in the heart and kidneys. This review presents the current data about the variety of MCR hyperactivation manifestations, as well as about of multiplicity of MCR hyperactivation ways in DM. The efficacy and safety of finerenone, a new MCR nonsteroidal selective antagonist, are discussed.
Keyphrases
- escherichia coli
- chronic kidney disease
- klebsiella pneumoniae
- multidrug resistant
- glycemic control
- end stage renal disease
- angiotensin converting enzyme
- angiotensin ii
- risk factors
- oxidative stress
- type diabetes
- poor prognosis
- signaling pathway
- big data
- metabolic syndrome
- combination therapy
- adipose tissue
- liver fibrosis